Bavarian Nordic Wins HHS Project BioShield Contract For Imvamune Smallpox Vaccine

Five-year contract could be worth $1.6 billion for the third-generation smallpox vaccine, to be stockpiled by the U.S. government for pandemic and terrorism preparedness.